Komori
Management planning4574TAIKO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice regarding approval of the change in market segment to the Standard Market and withdrawal of the plan to meet the Prime Market continued-listing criteria

The Tokyo Stock Exchange approved the change in market segment to the Standard Market, effective 2 November 2026. Accordingly, the plan to meet the Prime Market continued-listing criteria was withdrawn.

Worth reading
15Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Items stated in the management plan

Withdrawn
Plan to meet the Prime Market continued-listing criteria (under the improvement period)
Publication date 26 October 2026
Reason for revision or withdrawal

Following approval of the change in market segment to the Standard Market, the company will withdraw the plan as of today.

Items stated in the management plan
ItemDetails
Plan namePlan to meet the Prime Market continued-listing criteria (under the improvement period)
Progress against the planWithdrawn
Reason for revision or withdrawalFollowing approval of the change in market segment to the Standard Market, the company will withdraw the plan as of today.
Publication date26 October 2026
Items this document does not state (21)
Plan periodSales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsPlan assumptionsKey initiativesResults under the previous planSize of the Target MarketRisks identifiedDate of board resolution

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company determined that the Standard Market is better suited to its current business scale and growth stage, based on its current size, business environment and future growth strategy. In addition, following approval of the change in market segment to the Standard Market, the company withdrew its plan to meet the Prime Market continued-listing criteria.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice regarding approval of the change in market segment to the Standard Market and withdrawal of the plan to meet the Prime Market continued-listing criteria | TAIKO PHARMACEUTICAL CO.,LTD. (4574) timely disclosure | Komori